Trial Profile
An Exploratory and Open Clinical Study of Apatinib Mesylate as First-line Treatment for Advanced Esophagus Cancer.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Cisplatin; Fluorouracil
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Jun 2018 Planned initiation date changed from 1 May 2018 to 30 Jun 2018.
- 04 Jun 2018 New trial record